Cargando…

Role of hormonal risk factors in HER2-positive breast carcinomas

Examination of parity, age at menarche and at menopause by HER2 status in a large series of breast carcinomas showed a statistically significant increased-frequency of HER2-positive tumours in lower risk subgroups. The findings suggest a difference in the protective role of hormone-related risk fact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balsari, A, Casalini, P, Bufalino, R, Berrino, F, Ménard, S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376362/ https://www.ncbi.nlm.nih.gov/pubmed/12671699 http://dx.doi.org/10.1038/sj.bjc.6600844

Ejemplares similares

Identification of HER2-positive breast carcinomas as a particular subset with peculiar clinical behaviours
por: Casalini, P, et al.
Publicado: (2001)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

Rescue of HER-2-positive breast carcinoma cells from dormancy by growth factors produced during wound healing
por: Agresti, R, et al.
Publicado: (2001)

Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands
por: van Dooijeweert, Carmen, et al.
Publicado: (2019)

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
por: Kaufman, Peter A., et al.
Publicado: (2012)

A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
por: Honkanen, Tiia J., et al.
Publicado: (2021)

Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models
por: Laas, E, et al.
Publicado: (2015)

HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series
por: Rothschild, Harriet T., et al.
Publicado: (2023)

Prognostic value of morphology and hormone receptor status in breast cancer – a population-based study
por: Allemani, C, et al.
Publicado: (2004)

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
por: Alanko, Johanna, et al.
Publicado: (2021)

Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
por: Kaplan, Henry G., et al.
Publicado: (2022)

Multivariate analysis of independent roles of socioeconomic status, occupational physical activity, reproductive factors, and postmenopausal hormonal therapy in risk of breast cancer
por: Katuwal, Sushmita, et al.
Publicado: (2022)

Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies
Publicado: (2011)

Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer
por: Onland-Moret, N C, et al.
Publicado: (2003)

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer
por: Yardley, Denise A., et al.
Publicado: (2014)

Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
por: Colomer, R., et al.
Publicado: (2017)

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry
por: Ibragimova, Khava I. E., et al.
Publicado: (2023)

Hormonal risk factors and invasive epithelial ovarian cancer risk by parity
por: Bodelon, C, et al.
Publicado: (2013)

Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry
por: Ibragimova, Khava I. E., et al.
Publicado: (2021)

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
por: Bouwer, N. I., et al.
Publicado: (2021)

The hormonal profile of benign breast disease
por: Samoli, E, et al.
Publicado: (2013)

An overview of menopausal oestrogen–progestin hormone therapy and breast cancer risk
por: Lee, S A, et al.
Publicado: (2005)

A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population
por: Chen, Ruixian, et al.
Publicado: (2022)

Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment
por: Rubino, C, et al.
Publicado: (2003)

Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?
por: Jones, Michael E, et al.
Publicado: (2016)

Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer
por: Franks, Jeffrey, et al.
Publicado: (2022)

Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project
por: McGlynn, K A, et al.
Publicado: (2015)

Hormonal content and potency of oral contraceptives and breast cancer risk among young women
por: Althuis, M D, et al.
Publicado: (2003)

Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study
por: Ewertz, M, et al.
Publicado: (2005)

Long-term weight change and breast cancer risk: the European prospective investigation into cancer and nutrition (EPIC)
por: Lahmann, P H, et al.
Publicado: (2005)

Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
por: Gallagher, Christopher M., et al.
Publicado: (2016)

Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer
por: Lundgren, Christine, et al.
Publicado: (2019)

Association of size at birth with adolescent hormone levels, body size and age at menarche: relevance for breast cancer risk
por: Opdahl, S, et al.
Publicado: (2008)

Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
por: Dackus, Gwen M. H. E., et al.
Publicado: (2020)

Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors
por: Truin, Wilfred, et al.
Publicado: (2017)

Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study
por: Schiza, Aglaia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8g1pej6aj5t12b15tsgg29jj5v